

Remarks

Claims 19 and 20 are currently pending in the application. Claim 19 was indicated by the Examiner as being allowable. Claim 20 has been amended to correct an inadvertent error. Clearly, the reference to R1 and R2 is meant to include R1a, R1b, R2a and R2b.

Information Disclosure Statement

I. The information disclosure statement was objected to for failure to comply with CFR 1.98(a)(2).

Applicant has submitted herewith a new Information Disclosure Statement, with the requisite fee authorization, that includes an Abstract in English of the Foreign patent reference SU460724A and copies of the missing references (AJ, AP, AT, AV, AW, AX and AZ).

Specification

I. The Abstract was objected to for improper content.

Applicant has amended the Abstract to reflect the current subject matter of the pending claims.

II. The previous amendment to the specification was objected to for illegible text.

Applicants have resubmitted the amendment to the specification so that the lines overwritten by the FAX machine in the previous amendment can be read.

§112 Rejections

I. Claim 20 was rejected under 35 USC §112, second paragraph as being indefinite.

Examiner correctly points out an inadvertent error in Claim 20 where a reference is made to R1 and R2. Clearly, Applicant meant to refer to substituents R1a, R1b, R2a, and R2b. Applicant respectfully submits that the correction of this inadvertent error via amendment renders the rejection moot.

§102 Rejections

I. Claim 20 was rejected under 35 USC §102(b) as being anticipated by Nanuto, et al., Tetrahedron Letters 39, 3399-3409 (1975).


Applicant has amended Claim 20 to make it clear that the proviso eliminates the compound where R1a, R1b, R2a and R2b are all hydrogen. Applicants respectfully submit that the correction of the error renders this rejection moot since the compound cited as being anticipatory (i.e., example 8 on page 3401 of Nanuto) does not form a part of the claim.

Applicant respectfully submits that Claims 19 and 20 are both allowable and request a timely notice of allowance.

Date:

August 2, 2005

Respectfully Submitted:



Arlene K. Musser
Attorney for Applicants
Registration No. 37,895

Pfizer Inc.
Patent Department, MS: 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871